GLP-1 Muscle Loss Risk Calculator

The 39% Problem: Why Lean Mass Loss Matters

GLP-1 receptor agonists — semaglutide (sold as Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound) — are among the most effective weight loss tools ever developed. In clinical trials, patients losing 15–25% of body weight in 12–18 months. But this dramatic weight loss comes with a documented cost: a significant portion of that lost weight is lean mass rather than pure fat.

Research published in peer-reviewed journals has consistently found that without adequate protein intake and resistance exercise, up to 39% of weight lost on GLP-1 medications can be lean tissue — including skeletal muscle, bone mineral density, and organ mass. This matters for several reasons:

• Reduced resting metabolic rate — every pound of muscle burns approximately 6 kcal/day at rest; losing 10 lbs of muscle reduces your metabolism by ~60 kcal/day
• Increased rebound weight gain — lower muscle mass after stopping GLP-1 medication makes weight regain more likely and harder to reverse
• Impaired physical function — especially in older adults, lean mass loss directly worsens strength, balance, and independence
• Bone density loss — rapid weight loss from any cause reduces bone mineral density, increasing fracture risk

The Five Risk Factors Driving Lean Mass Loss

This calculator evaluates five evidence-based risk factors that determine how much lean mass you are likely to lose on a GLP-1 medication:

How to Achieve “Lean Loss” — Fat Without Muscle

The goal of any weight loss intervention should be to lose fat while preserving as much lean mass as possible. On GLP-1 medications, this requires a deliberate three-pronged strategy:

• Protein first: Target 1.4–1.6 g/kg of body weight daily. Distribute across 3–4 meals with 30–50g per meal. On days when appetite is very low, use liquid protein sources — shakes, Greek yogurt, or cottage cheese.
• Resistance training 3–4x/week: Compound movements (squats, deadlifts, rows, presses) provide the greatest muscle-preservation stimulus. Even short 30-minute sessions deliver significant protection.
• Manage the deficit: If your spontaneous deficit on GLP-1 medications appears to exceed 750 kcal/day, work with your prescribing physician on timing, meal structure, or dosing to moderate the rate of weight loss to 0.5–1.5 lbs per week.

Special Considerations for Adults Over 60 on GLP-1 Medications

Older adults face the highest lean mass loss risk on GLP-1 medications due to the combination of anabolic resistance, pre-existing age-related muscle loss (sarcopenia), and often lower baseline activity levels. For this population, additional considerations apply:

• Increase protein per meal to 35–50g to overcome the blunted anabolic response — standard 25g doses may be insufficient.
• Leucine-rich protein sources (whey protein, chicken, beef, milk) are especially effective at stimulating muscle protein synthesis in older adults.
• Prioritize balance and functional training in addition to traditional resistance work to reduce fall risk if baseline muscle function is already impaired.
• Request regular DEXA scans or bioelectrical impedance assessments from your healthcare provider to monitor body composition changes every 3–6 months.

What to Expect After Stopping GLP-1 Medications

One of the most important reasons to minimize lean mass loss while on GLP-1 medications is the well-documented weight rebound that occurs when these medications are discontinued. Preserving muscle mass provides critical metabolic protection:

Patients who maintained their lean mass while on GLP-1 treatment show substantially lower weight regain rates after stopping, because their maintained metabolic rate requires more calories to sustain. Conversely, patients who lost significant lean mass regain weight faster and reach a higher set point than before medication.

Building and maintaining muscle while on GLP-1 medications is therefore an investment not just in current health but in long-term weight maintenance after treatment ends.